FEDERAL COURT OF AUSTRALIA
Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 6) [2024] FCA 480
File number: NSD 656 of 2017 Judgment of: NICHOLAS J Date of judgment: 10 May 2024 Catchwords: PATENTS – appropriate form of declaration of infringement – amendment of claim for additional damages – whether outside terms of leave previously granted – whether costs relating to preparation of written evidence should be reduced – whether such costs unreasonably or unnecessarily incurred Legislation: Federal Court Rules 2011 (Cth) r 40.30
Patents Act 1990 (Cth) ss 13(1), 19(1), 117, 122
Cases cited: Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 4) [2020] FCA 1776
Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360
Division: General Division Registry: New South Wales National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Number of paragraphs: 22 Date of hearing: 2 May 2024 Counsel for the Applicant/Cross-Respondent: Mr D Shavin KC with Ms M Evetts Solicitor for the Applicant/Cross-Respondent: DLA Piper Australia Counsel for the Respondents/Cross-Claimants: Mr N Murray SC Solicitor for the Respondents/Cross-Claimants: Herbert Smith Freehills ORDERS
NSD 656 of 2017 BETWEEN: NEURIM PHARMACEUTICALS (1991) LTD
Applicant
AND: GENERIC PARTNERS PTY LTD (ACN 132 833 777)
First Respondent
APOTEX PTY LTD (ACN 096 916 148)
Second Respondent
AND BETWEEN: APOTEX PTY LTD (ACN 096 916 148)
Cross-Claimant
AND: NEURIM PHARMACEUTICALS (1991) LTD
Cross-Respondent
AND BETWEEN: GENERIC PARTNERS PTY LTD (ACN 132 833 777)
Cross-Claimant
AND: NEURIM PHARMACEUTICALS (1991) LTD
Cross-Respondent
ORDER MADE BY:
NICHOLAS J
DATE OF ORDER:
10 MAY 2024
THE COURT DECLARES THAT:
1.The respondents, acting in concert and pursuant to a common design, infringed claims 4-7 of Australian Patent No. 2002326114 entitled “Method for treating primary insomnia” (“the Patent”):
(a)Pursuant to s 117(2)(b) of the Patents Act 1990 (Cth) (“the Act”), by the supply of Melotin where the respondents had reason to believe that it would be prescribed by a not insignificant number of psychiatrists as a treatment for primary insomnia where the patient complained of non-restorative (or unrefreshing) sleep; and
(b)Pursuant to s 13(1) of the Act, by authorisation of medical practitioners whom the respondents had reason to believe would use Melotin as a treatment for primary insomnia characterised by non-restorative sleep and to improve the restorative quality of sleep in patients aged 55 and over.
THE COURT ORDERS THAT:
2.The cross-claims be dismissed.
3.There be an inquiry as to the quantum of any damages to which the applicant is entitled pursuant to ss 122(1) and 122(1A) of the Act, or, at the election of the applicant, an account of profits in respect of the supply by the respondents during the term of the Patent of any Generic Partners Products or Apotex Products as defined in [5] and [6] of Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360.
4.The respondents are granted leave to appeal the declaration and orders in paras 1-3 hereof.
5.Any notice of appeal that is…
Keep reading for free
Create a free CaseChat account to read Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] FCA 480
- Decision Date
CaseChat Overview and Summary
The court held that the plaintiff was permitted to amend its claim for additional damages, as it fell within the scope of the leave previously granted. The court found that the costs incurred for the preparation of written evidence were not unreasonable or unnecessary, and therefore, there was no basis to reduce these costs. The court dismissed the cross-claims and ordered an inquiry into the quantum of any damages to which the plaintiff was entitled. The court granted leave for the respondents to appeal the declaration and orders, and directed that any notice of appeal be filed within 28 days. The court further ordered that the applicant's undertaking to the court be discharged and that the applicant's provision of security for the respondents' costs be released. The court also granted the applicant leave to file and serve its further amended statement of claim, subject to certain deletions.
The final orders of the court included the dismissal of the cross-claims, an inquiry into the quantum of any damages to which the plaintiff was entitled, and an order for the respondents to pay the applicant's costs of the proceeding to date, subject to certain exceptions. The court certified that the validity of claims 1 to 7 of the patent was not successfully questioned in the proceeding.
Orders
Orders of the court
2. The cross-claims be dismissed.
3. There be an inquiry as to the quantum of any damages to which the applicant is entitled pursuant to ss 122(1) and 122(1A) of the Act, or, at the election of the applicant, an account of profits in respect of the supply by the respondents during the term of the Patent of any Generic Partners Products or Apotex Products as defined in [5] and [6] of Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360.
4. The respondents are granted leave to appeal the declaration and orders in paras 1-3 hereof.
5. Any notice of appeal that is to be filed pursuant to order 4 hereof be filed and served within 28 days.
6. Order 3 be stayed until the later of:
(a) 28 days from the date of these orders; or
(b) if a notice of appeal is filed within 28 days, until the final determination of any appeal (including any application for special leave to appeal to the High Court of Australia).
7. If no notice of appeal is filed within 28 days from the date of these orders, there be a further directions hearing in relation to the matters referred to in order 3 of these orders on a date to be fixed.
8. The applicant’s undertaking to the Court given on 9 May 2017, and noted in paragraph 4 of the Orders dated 18 July 2017, be discharged.
9. The applicant’s provision of security for the respondents’ costs of and incidental to these proceedings and the respondents’ damages pursuant to the applicant’s undertaking to the Court be released.
10. The applicant be granted leave to file and serve its Further Amended Statement of Claim including para 45A subject to the deletions referred to in [14] of the reasons published today being made.
11. The respondents pay the applicant’s costs of the proceeding (including the costs of the cross-claims and any costs reserved) to date save for:
(a) the costs reserved on 11 December 2020 which are to be determined at the same time as the applicant’s claim for pecuniary relief is determined; and
(b) the costs of the hearing on 2 May 2024 as to which there will be no order as to costs.
AND THE COURT CERTIFIES:
12. Pursuant to s 19(1) of the Act, the validity of each of claims 1 to 7 of the Patent was questioned unsuccessfully in this proceeding.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi